Integrated single-cell transcriptomic analysis of brain and lymph node metastases in non-small cell lung cancer

Table 2 Multiplex immunohistochemistry cohorts

Group	Pathological number	Gender	Age (years)	Histology	Stage	TNM	Treatment regimens
Mets0	1037557	Male	58	ADC	I	T2aN0M0	Surgery
Mets0	1054412	Female	82	ADC	II	T2N0M0	Surgery
Mets0	1117778	Female	48	ADC	I	T2aN0M0	Surgery
Mets0	1117102	Female	61	ADC	I	T1N0M0	Surgery
Mets0	1123096	Male	58	ADC	I	T1N0M0	Surgery
Mets0	1121625	Male	51	ADC	II	T3N0M0	Chemotherapy
Mets0	1088996	Male	70	ADC	I	T1N0M0	Surgery
Mets0	1119756	Female	54	ADC	I	T1N0M0	Surgery
Mets0	1124448	Male	61	ADC	II	T2bN0M0	Surgery
Mets0	1136112	Male	68	ADC	II	T2bN0M0	Chemotherapy
Mets0	1135011	Male	60	ADC	II	T2bN0M0	Chemotherapy
Mets1	1090522	Female	48	ADC	III	T2aN2M0	Chemotherapy
Mets1	1092316	Female	53	ADC	II	T2aN1M0	Surgery
Mets1	641032	Male	50	ADC	IV	T1bN3M1b	Chemotherapy
Mets1	1099920	Female	50	ADC	II	T1bN1M0	Surgery
Mets1	1113168	Female	53	ADC	III	T2N2M0	Surgery
Mets1	1118269	Male	40	ADC	II	T2aN1M0	Surgery
Mets1	1120708	Female	58	ADC	III	T3N1M0	Surgery
Mets1	1117066	Female	79	ADC	IV	T2N1M1	Surgery
Mets1	1113386	Male	62	ADC	III	T3N2M0	Surgery
Mets1	1131710	Male	52	ADC	III	TIcN2M0	Surgery
Mets1	1128781	Male	63	ADC	III	T3N2M0	Surgery
Mets1	1145641	Male	43	ADC	II	T2N1M0	Surgery

ADC: Adenocarcinoma.